Lantern Pharma Inc. (LTRN): Price and Financial Metrics


Lantern Pharma Inc. (LTRN): $5.87

-0.13 (-2.17%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add LTRN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

LTRN Stock Price Chart Interactive Chart >

Price chart for LTRN

LTRN Price/Volume Stats

Current price $5.87 52-week high $7.92
Prev. close $6.00 52-week low $4.19
Day low $5.73 Volume 10,364
Day high $6.00 Avg. volume 44,344
50-day MA $5.45 Dividend yield N/A
200-day MA $5.36 Market Cap 63.73M

Lantern Pharma Inc. (LTRN) Company Bio


Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-11, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.


LTRN Latest News Stream


Event/Time News Detail
Loading, please wait...

LTRN Latest Social Stream


Loading social stream, please wait...

View Full LTRN Social Stream

Latest LTRN News From Around the Web

Below are the latest news stories about LANTERN PHARMA INC that investors may wish to consider to help them evaluate LTRN as an investment opportunity.

LTRN: LP-184 & LP-284 in the Spotlight

By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT Recent Program Updates Since Lantern Pharma, Inc. (NASDAQ:LTRN) announced 3Q:22 results in early November, there have been a number of program updates for LP-184 and LP-284. In late November, Lantern announced positive data regarding the anti-tumor potency of LP-184 in glioblastoma (GBM) and a few weeks later highlighted

Yahoo | February 1, 2023

Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate LP-184’s Phase 1 Clinical Trial in Q2 2023

DALLAS, January 17, 2023--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning ("M.L.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it has received guidance from the United States Food and Drug Administration (FDA) on Lantern’s clinical development plans for its LP-184 program. LP-184 has shown nanomolar potency across a ra

Yahoo | January 17, 2023

Should Lantern Pharma Inc. (NASDAQ: LTRN) Investors Be Concerned?

The trading price of Lantern Pharma Inc. (NASDAQ:LTRN) closed higher on Friday, January 13, closing at $5.48, 0.92% higher than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $5.42 and $5.64. In examining the 52-week price action we see that the stock hit a 52-week … Should Lantern Pharma Inc. (NASDAQ: LTRN) Investors Be Concerned? Read More »

Stocks Register | January 16, 2023

FDA grants orphan drug designation to Lantern Pharma''s lymphoma treatment candidate

Lantern Pharma (LTRN) said the U.S. FDA had granted an orphan drug designation to its LP-284 candidate for the treatment of mantle cell lymphoma. Read more here.

Seeking Alpha | January 5, 2023

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma

DALLAS, January 05, 2023--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning ("M.L.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted LP-284 Orphan Drug Designation (ODD) for the treatment of mantle cell lymphoma (MCL). MCL is a rare and aggressive form of B-cell no

Yahoo | January 5, 2023

Read More 'LTRN' Stories Here

LTRN Price Returns

1-mo 5.77%
3-mo 36.83%
6-mo -3.61%
1-year -13.42%
3-year N/A
5-year N/A
YTD -2.81%
2022 -24.31%
2021 -58.55%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6695 seconds.